Circulation, Vol 85, 1912-1917, Copyright © 1992 by American Heart Association
MA Lloyd, SM Sandberg and BS Edwards
BACKGROUND. Cardiac glycosides have traditionally been used as inotropic
agents in the treatment of congestive heart failure (CHF). The renal
actions of cardiac glycosides independent of inotropic effects are not
characterized. The presence of endogenous digitalis- like factors (EDLFs)
with characteristic Na+,K(+)-ATPase activity has been postulated in
volume-expanded states such as CHF, and recent studies have demonstrated
that at least one EDLF shares structural homology with ouabain. This study
was undertaken to evaluate the renal actions of ouabain in normal dogs and
those with CHF. METHODS AND RESULTS. After surgical preparation, normal
dogs (n = 6) and dogs in pacing-induced CHF (n = 6) received intrarenal
ouabain in sequential doses of 0.167 micrograms/kg/min, 0.334
micrograms/kg/min, and 0.668 micrograms/kg/min. Hemodynamics and renal
function were evaluated during the infusion. There was no change in heart
rate or mean arterial pressure during the infusion compared with baseline
in both groups. Sodium excretion and urine volume significantly increased
in both groups. Plasma renin activity, activated by the onset of pacing in
the CHF group, was inhibited by the administration of intrarenal ouabain in
this group only. CONCLUSIONS. These studies demonstrate that ouabain has
diuretic and natriuretic actions independent of cardiac hemodynamics that
are preserved in CHF. Furthermore, intrarenal ouabain suppresses activation
of renin in CHF.
ARTICLES
Role of renal Na+,K(+)-ATPase in the regulation of sodium excretion under normal conditions and in acute congestive heart failure
Department of Cardiovascular Diseases, Mayo Clinic and Foundation, Rochester, Minn. 55905.
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1992 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |